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Abstract 
The vast majority of connections between complex disease and common genetic variants were 
identified through meta-analysis, a powerful approach that enables large samples sizes while 
protecting against common artifacts due to population structure, repeated small sample analyses, 
and/or limitations with sharing individual level data. As the focus of genetic association studies 
shifts to rare variants, genes and other functional units are becoming the unit of analysis. Here, we 
propose and evaluate new approaches for meta-analysis of rare variant association. We show that 
our approach retains useful features of single variant meta-analytic approaches and demonstrate 
its utility in a study of blood lipid levels in ~18,500 individuals genotyped with exome arrays.  
Proceeding from the discovery of a genetic association signal to a mechanistic insight about 
human biology should be much easier for alleles with clear functional consequence, including non-
synonymous, splice altering and protein truncating alleles. Most of these alleles are very rare, with only 
one such allele expected to reach MAF>5% in the average human gene1.  Recent advances in exome 
sequencing and the development of exome genotyping arrays are enabling explorations of the very large 
reservoir of rare coding variants in humans and are expected to accelerate the pace of discovery in human 
genetics2. 
 Rare variants can be examined using association tests that group alleles in a gene or other 
functional unit3. Compared to tests of individual alleles, this grouping can increase power, especially 
when applied to large samples where several rare variants are observed in the same functional unit4. The 
simplest rare variant tests consider the number of potentially functional alleles in each individual5, but the 
tests can be refined to weigh variants according to their likely functional impact6, to allow for imputed or 
uncertain genotypes7,8, or to allow variants that increase and decrease risk to reside in the same gene9-11  (a 
feature that is important when the same gene harbors hypermorph and hypomorph alleles12). The optimal 
strategy for grouping and weighting rare variants – ranging from focusing on protein truncation alleles to 
examining all non-synonymous variants and encompassing strategies that examine all variants with 
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frequency <5% as well as alternatives that examine only singletons – depends on the unknown genetic 
architecture of each trait and each locus.  
 Here, we describe practical approaches for meta-analysis of rare variants. Our approach starts 
with simple statistics that can be calculated in an individual study. We then show that, when these 
statistics are shared, a wide variety of gene-level association tests can be executed centrally – including 
both weighted or un-weighted burden tests with fixed5 or variable frequency threshold6 and sequence 
kernel association tests (SKAT) that accommodate alleles with opposite effects within a gene9. Our 
approach generates comparable results to sharing individual level data (and, in fact, identical results when 
allowing for between study heterogeneity in nuisance parameters, such as trait means, variances and 
covariate effects). As an illustration of our approach, we analyze blood lipid levels in >18,500 individuals 
genotyped with exome genotyping arrays. Our analysis of blood lipid levels provides examples of loci 
where signal for gene-level association tests exceeds signal for single variant tests and shows that our 
approach can recover signals driven by very rare variants (frequency <0.05%). Given that very large 
sample sizes are required for successful rare variant association studies, we expect our methods (and 
refined versions thereof) will be widely useful. 
 Our approach is based on the insight that analogues of most gene level association tests can be 
constructed using single variant test statistics and knowledge of linkage disequilibrium relationships. As 
shown in Online Methods, simple13 and weighted10,14 burden tests, variable threshold tests6 and tests 
allowing for variants with opposite effects9 can be constructed in this manner. We meta-analyze single 
variant statistics using the Cochran-Mantel-Haenszel method, calculate variance-covariance matrices for 
these statistics, and construct gene-level association tests by combining the two. In Supplementary 
Material, we show that rare variant statistics generated in this way identical to those obtained by sharing 
individual level data and allowing for heterogeneity in nuisance parameters, with no loss of power. As in 
other meta-analysis settings, sharing summary statistics accelerates the overall analysis process, mitigates 
concerns about participant confidentiality, and reduces the risk that data will be used for unapproved 
analyses (as always, to avoid violating the trust of research subjects, we strongly recommend that 
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investigators sharing summary statistics agree that these will not be used to identify research subjects). 
For evaluating significance, we propose methods for calculating p-values using asymptotics and also 
Monte-Carlo methods that use knowledge of linkage disequilibrium relationships to sample plausible 
combinations of single variant statistics and then generate empirical distributions for our gene-level 
statistics. Since asymptotic p-values rely on numerical integration to evaluate high-dimensional integrals 
that can be numerically unstable, Monte-Carlo methods can be used to verify interesting p-values. 
 We first evaluated our method using simulations. Genes were simulated as stretches of 5,000 
base-pairs using the coalescent15 and a demographic model (including an ancient bottleneck, recent 
exponential growth, differentiation and migration) calibrated to mimic a sample of multiple European 
populations16,17 (Supplementary Figure 1 and Supplementary Material).  The simulations produced 
samples of 1,000 individuals, each from several related populations, typically including a few shared 
variants and many population specific variants – as expected when the distribution of rare variants is 
geographically restricted18. Half of the simulated variants were randomly set to increase trait values by 
1/8th of a standard deviation (see Supplementary Figure 2 and 3 for similar results using alternative trait 
models). 
 We analyzed each simulated sample with a series of gene-level association tests.  Figure 1 
compares results obtained for 10,000 simulated genes using our meta-analysis approach to a combined 
analysis of individual level data across studies. For variable threshold tests, we found the p-values were 
sometimes slightly different (r2=0.995 between the two sets of log p-values); for the other two tests p-
values and test statistics were indistinguishable. Calculation of analytical p-values for variable threshold 
tests requires the evaluation of high-dimensional integrals that can be numerically unstable and is thus 
very sensitive to small differences in the variance-covariance matrix. In practice, it will often be a good 
idea to confirm significant p-values using our Monte-Carlo approach.  
 To evaluate our Monte-Carlo approach, we compared its empirical p-values to those obtained by 
permuting phenotypes between individuals within each study. We implemented adaptive versions of both 
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algorithms19, with more simulations carried out when the p-value is small and fewer simulations when the 
p-value is large. Log p-values for the two approaches are highly concordant (r2=0.996).  
We next evaluated the type I error and power under a variety of models. Supplemental Table 1 
shows that type I error is well controlled. Supplemental Figures 4 and 5 summarize power for various 
simulation scenarios and meta-analysis of 3 to 100 samples of 1000 individuals each. Power always 
increases as more studies are analyzed. It is clear that, for the effect sizes simulated here, very large 
samples may be required. In some settings, power only reaches ~60% in analyses of ~100,000 
individuals. In addition, we did not find a universally most powerful method, emphasizing the value of 
implementing a diverse set of test statistics. Supplemental Figure 6 shows that, as expected, our meta-
analysis of summary statistics results in the same power as joint-analysis of individual data. 
Supplemental Figure 7 shows our approach outperforms simpler meta-analysis methods, such as those 
based on Fisher’s method for combining p-values, in an analysis of three equal sized samples; the 
advantages of our method increase when studies are unequal in size and/or the number of studies rises.  
We proceeded to a meta-analysis of blood lipid levels in 18,699 individuals of European ancestry 
genotyped with Illumina Exome arrays and drawn from 7 studies:  the Women’s Health Initiative20, the 
Ottawa Heart Study21, the Malmö Diet and Cancer Study – Cardiovascular Cohort (MDC)22, the 
PROCARDIS Precocious Coronary Artery Disease Case Series, PROCARDIS Control series23 and the 
Nord-Trøndelag Health Study (HUNT) myocardial infraction cases and matched controls24 (see 
Supplemental Table 2 and 3 for summary statistics for each of these samples, including basic 
demographics, summaries of lipid levels, number of non-synonymous and loss-of-function variants per 
individual and of variants sites shared across different studies). Overall, 171,193 variants were 
polymorphic in at least one individual. Among these variants, 125,702 – the vast majority – have 
frequency <1%.   
To verify the soundness of our approach, we first compared joint analysis of individual level data 
to meta-analysis by splitting the largest sample (MDC) into 4 sub-samples. To mimic our meta-analysis 
protocol, we normal transformed trait values in each sub-sample and generated summary statistics, which 
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were then meta-analyzed and used for gene level tests. We carried out a parallel analysis examining all 
individual level data jointly. Reassuringly, p-values from the two approaches are highly concordant with 
r2>0.99 (Supplemental Figure 8).  
We then proceeded to meta-analyze single variant association test results. The resulting test 
statistics appear well calibrated, with genomic control value <1.05 for all three traits (Supplemental 
Figure 9). At a significance threshold of p<3x10-7 (corresponding to 0.05 / 171,193), we found 
significantly associated variants (with MAF<5%) at LPL, ANGPTL4, LIPG, CD300LG, LIPC, APOB, 
HNF4A for HDL; PCSK9, BCAM-CBLC-PVR (neighboring APOE), and APOB for LDL; ANGPTL4, 
LPL, APOB, and MAP1A for TG (Supplemental Table 4). Except for the variants in LIPC and APOB, all 
other significantly associated variants have frequency of >1% reflecting the limited power of single 
variant association tests for rare alleles.  
We next carried out gene-level tests. Again, test statistics appear well calibrated, with genomic 
control value <1.05 (Supplemental Figure 10). At a significance threshold of p <3.1x10-6 (corresponding 
to 0.05 / 16,153 and thus allowing for the number of genes tested), we observed association at ANGPTL4, 
LIPC, LIPG, HNF4A, CD300LG and LPL for HDL, at the APOE-locus (as well as nearby genes PVR, 
BCAM, and CBLC), PCSK9 and LDLR for LDL, and at ANGPTL4, APOB and LPL for triglycerides 
(Table 1). Supplemental Table 5 emphasizes that, at these loci, much stronger signals are identified in 
meta-analysis than in any component study. Reassuringly, these signals point to loci identified in previous 
genome-wide association studies and/or re-sequencing studies. Importantly, note that our approach was 
able to appropriately identify the signal in LDLR which is driven by several very rare variants (each with 
frequency < .00052) that nearly always increase blood LDL cholesterol levels and that, at several other 
loci, gene-level p-values exceeded the best single variant p-value in the gene (Supplemental Table 6).   
An added convenience of sharing single-variant statistics together with their covariance matrices, 
as we propose, is that it facilitates conditional analyses, extending an idea used by Yang et al25 for 
analysis of common variants in GWAS meta-analysis. Supplemental Figure 8 illustrates how, in 
simulations, common variants can generate shadow rare variant association signals at nearby genes, and 
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how our method for conditional analysis resolves the problem. In real data, we re-examined two loci of 
the LDL associated loci in detail, LDLR and APOE-BCAM-CBLC-PVR. For LDLR, we examined the 
relationship between rare variant signals and three nearby common variants26. Specifically, we 
conditioned on genotypes for 3 common variants (rs6511720, rs2228671 and rs72658855) exhibiting 
significant association in the region, and found that LDLR rare variant association remains significant (p-
value 4.6×10-7) (Supplemental Table 7). For the APOE-BCAM-CBLC-PVR locus, after conditioning on 
the common variant showing strongest association in the region (rs7412), gene-level associations at 
BCAM, CLBC and PVR become non-significant, suggesting that these rare-variant signals are the result of 
regional linkage equilibrium with more common and well described variants in APOE (Supplemental 
Table 8). For completeness, Supplemental Figure 12 and 13 show that conditional analyses using 
individual level data of MDC and conditional meta-analyses of 4 sub-samples give highly concordant 
(r2>0.99).  
Our methods are implemented freely available software, including programs for calculating 
summary statistics, annotating the resulting summaries, performing meta-analysis and calculating gene-
level statistics, and executing conditional analyses. Our tools work with standard VCF files10,27 and 
Merlin format files28.  
Meta-analysis has facilitated many discoveries in common variant association studies. Here, we 
describe a powerful framework for meta-analysis of rare variants at the level of genes or other functional 
units. Through simulation and empirical evaluation, we demonstrate that our approach is well calibrated 
and provides comparable power to more cumbersome analyses that require pooling all individual level 
data. Through the analysis of blood lipids levels across seven studies, we show that our approach can 
detect rare variant association signals at known candidate loci. We envision that this approach will 
facilitate the large sample sizes required to accelerate new discoveries in complex trait genetics.  
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Figure legend 
Figure 1: Scatter plot of statistics and p-values for a simple burden test grouping variants with MAF < 1% 
(burden-1), variable threshold tests (VT) and tests allowing for variants with opposite effects (SKAT) in 
meta-analysis and joint-analysis of individual data. Three samples of 1000 European-ancestry individuals 
were simulated. Traits were simulated assuming that 50% of the variants in the gene region are causal and 
that each causal variant increases trait means by 0.125 standard deviations. Empirical p-values for the VT 
were obtained using our Monte-Carlo procedure to generate replicates until 100 simulated statistics 
exceeded the original observation or 40,000,000 statistics were simulated.  
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Table 1: Results for meta-analysis of gene-level rare variant association test. Associations that attain exome-wide significance (p < 3.1×10-6 ) are 
displayed. Five gene-level association tests were used to analyze the data: simple burden tests with 1% or 5% cutoff (Burden-1 and Burden-5), 
SKAT tests with 1% or 5% cutoff (SKAT-1 and SKAT-5) and variable threshold (VT) tests that analyze variants with MAF<5%. Significant p-
values for each test are displayed in bold font. For the associations that are significant, estimates of average genetic effect are also shown.  
 
Gene Gene 
Positiona 
Burden-1 Burden-5 SKAT-1 SKAT-5 VT MAF 
Cutoff 
Direction of 
Single Variant 
Association 
Statisticsb 
Estimates of Genetic 
Average Effect (s.d units) 
for Rare Variants under 
Different MAF Thresholds 
0.01 0.05 VT 
HDL 
LIPC chr15:58.7Mb 1.4×10-12 3.5×10-7 1.8×10-9 1.4×10-2 4.5×10-12 3.7×10-3 -++++--+- 0.5 0.1 0.5 
LPL chr8:19.8Mb 9.7×10-1 2.5×10-24 3.5×10-1 5.0×10-13 1.5×10-23 2.5×10-2 (-)-(-)+-++ - -0.3 -0.3 
ANGPTL4 chr19:8.4Mb 2.2×10-2 2.9×10-19 2.2×10-2 3.0×10-19 1.8×10-18 2.6×10-2 (+)--++-+++ - 0.3 0.3 
LIPG chr18:47.1Mb 2.2×10-5 6.4×10-19 2.1×10-5 2.9×10-9 4.4×10-18 1.3×10-2 -++----(+)+ - 0.4 0.4 
HNF4A chr20:43.0Mb 7.5×10-1 2.8×10-7 6.8×10-1 2.5×10-7 1.5×10-6 4.1×10-2 (-)--+-+ - -0.1 -0.1 
CD300LG chr17:41.9Mb 4.9×10-1 8.5×10-7 5.2×10-1 1.0×10-5 3.1×10-6 3.3×10-2 (-)+-(+) - -0.1 - 
LDL 
PCSK9 chr1:55.5Mb 1.8×10-2 7.4×10-19 8.1×10-2 5.5×10-17 2.0×10-28 1.3×10-2 (-)--(-)--+-++- - -0.3 -0.5 
BCAM chr19:45.3Mb 1.7×10-1 1.6×10-18 1.5×10-1 3.0×10-5 2.6×10-17 3.6×10-2 (-)+++(-)+-+++---+(-)+--+--
++ 
- -0.1 -0.1 
CBLC chr19:45.3Mb 9.4×10-1 2.0×10-15 4.4×10-1 1.5×10-4 1.0×10-14 4.4×10-2 -(-)--+-(-)(+) - -0.1 -0.1 
PVR chr19:45.2Mb 6.1×10-2 3.0×10-10 4.8×10-2 6.3×10-2 1.1×10-9 4.9×10-2 (-)++--+ - -0.1 -0.1 
LDLR chr19:11.2Mb 1.8×10-3 4.7×10-5 3.8×10-2 2.5×10-1 2.4×10-7 5.2×10-4 +++++++++-++++--+ - - 0.8 
TG 
ANGPTL4 chr19:8.4Mb 2.6×10-2 1.2×10-24 3.7×10-2 3.9×10-25 7.1×10-24 2.6×10-2 (-)+---+--- - -0.3 -0.2 
LPL chr8:19.8Mb 6.8×10-1 7.7×10-20 2.6×10-1 1.8×10-11 4.6×10-19 2.5×10-2 (+)+(+)--+- - 0.2 0.2 
a. Gene position is defined based upon hg19, GRCh37 Genome Reference Consortium Human Reference 37 
b. Direction of single site statistics for variants with MAF<5%. Variants within parenthesis have frequency >1%.  
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Online Methods 
This section starts with a summary of notation, and proceeds to describe the statistics to be shared 
between studies and single variant meta-analysis. We then show that the joint analysis statistics for 
different gene-level tests can be calculated using summary level data, enabling efficient meta-analysis. In 
the Supplementary Material, we provide many additional details and summarize how each of the test 
statistics used here can be derived as a score test using joint likelihood functions that allow for per-sample 
nuisance parameters.  
 
Notation  
For simplicity, we describe our strategy for analysis of a single gene. Let J  be number of variant 
nucleotide sites genotyped in at least one study. For study k , let kN  denote the number of samples 
phenotyped and genotyped,
 
and let the vector ( )TkNkk kYYY ,,1 ,, =  denote the quantitative trait residuals 
(after adjustment for any covariates), with variance 2kσ .  Within each study, we encode genotype 
information in matrix Xk where each entry kjiX ,,  represents the genotype for individual i  at site j , coded 
as the number of alternative alleles. We encode missing genotypes in the dataset as the average number of 
minor alleles in individuals who are genotyped for that marker. The multi-site genotype for individual i  
is denoted by the row vector kiX ,,•

, and the genotypes for all kN  individuals at site j  are given by 
column vector kjX ,,•

. For the ease of presentation, we define the mean genotype matrix , where the 
),( ji -th element is ( ) ki kji NX∑ ,, .  
 
Summary Statistics To Be Shared
 
For each study, we first calculate and share a vector of score statistics ( ) kTk YU  −= , a 
corresponding variance-covariance matrix ( ) ( ) ( )−−== Tkkk N 22 ˆcovˆ σσ , and allele 
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frequencies for each marker ki kjikj NXp 2,,, ∑= . Note that  effectively describes linkage 
disequilibrium relationships between the variants being examined. To perform quality control, we also 
share mean and variance for the quantitative trait residuals and genotype call rate and Hardy-Weinberg 
equilibrium p-values at each variant site.  
 
Meta-analysis of Single Variant Association Test Statistics 
We first combine single variant association test statistics across studies using the Cochran-Mantel-
Haenszel method. Specifically, we calculate a score statistic at each site as: 
•••
=
,,,, jjjj VUT  
where ∑=• k kjj UU ,,  and ∑=• k kjjjj VV ,,,, . For ease of presentation, we denote the vector of single 
variant association tests after meta-analysis as ∑= k kUU

. Under the null, this vector is distributed as 
multivariate normal with mean vector 0

 and covariance matrix ∑k kV . 
 
Burden Tests That Assume Variants Have Similar Effect Sizes 
For a simple burden test in study k, the impact of multiple rare variants in a region can be modeled using a 
shared regression coefficient in a model that takes the form:  
( ) kikiBURDENBURDENkki XCY ,,,,0, εββ ++= • , where ( )2, ,0~ kki σε Ν   
 
 
( )kiBURDEN XC ,,•  is a function that takes genotypes for a single individual as input and returns the count of 
rare alleles (the “rare variant burden”) in the gene being examined. When individual level data is 
available and nuisance parameters k,0β  and 2kσ  are allowed to vary between studies, the score statistic 
for a rare variant burden test becomes: 
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UUUU T
k k
T
k kBURDENBURDEN

ωω === ∑∑ ,  
Under the null, this statistic is approximately normally distributed with mean 0 and variance
( )ωω  ∑= kTBURDENV , enabling significance tests. Here, ω  is the vector of weights, that is 
( )Jωωω ,,1  = , where jω  is the weight assigned to variant j according to its allele frequency or its 
computationally predicted functional impact10,14. The formula above makes it clear that, when nuisance 
parameters are allowed to vary between studies, the same burden score statistics that could be calculated 
by sharing individual data can be equivalently calculated using shared summary statistics.   
 
Variable Threshold Tests with an Adaptive Frequency Threshold 
In variable threshold tests, rare variant burden statistics are calculated for each observed variant minor 
allele frequency threshold and significance is evaluated for the maximum of these statistics. Given a 
specific variant frequency threshold F  we define the resulting burden score statistic as: 
UvU TFFBURDEN

=)( . 
Here, Fv

 is a vector of indicators where the jth element equals 1 if the pooled minor allele frequency at 
variant site j is less than F  and zero otherwise. For convenience, we also define a matrix of minor allele 
frequency thresholds ( )
JFFF
vvv
 ,,,
21
=Φ . After a burden statistic is calculated for each potential 
frequency threshold, these are standardized, dividing each statistic by its corresponding variance, and the 
maximum statistic is identified: 
{ },max )(FBURDENFVT TT =  where F
k
k
T
FFBURDENFBURDEN vvUT
 ∑= V)()( . 
 
Significance for this statistic can be evaluated using the cumulative distribution function for the 
multivariate normal distribution29. Specifically, given the definition of the covariance between burden 
statistics calculated using different allele frequency thresholds, we have: 
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( ) ( )( )ΦΦ ∑kTFBURDENFBURDEN MTT ,0MVN~,, )()( 1  . 
 
Burden Tests that Assume a Distribution of Variant Effect Sizes (e.g. SKAT tests) 
The simple burden test and variable threshold test described above can be underpowered when variants 
with opposite phenotypic effects reside in the same gene and are grouped together, because the shared 
regression coefficient can average close to zero in that situation. To accommodate this setting, we 
consider an underlying distribution of rare variance effect sizes with mean zero and test whether the 
variance of this distribution 2τ  is greater than zero. 
 
When individual level data is available, association analysis in study k is performed using the following 
model 
kij kjijkki XY ,,,,0, εββ ++= ∑ , where ( )2, ,0~ kki σε Ν   
We make inferences about rare variant effect sizes ( )Jββββ ,,, 21  =  by assuming these follow a 
common distribution with mean zero and variance 2τ . Under the null, 02 =τ . Following Wu et al9, in 
Supplementary Material we derive the score statistic for this model and show that it can be calculated 
on the basis of per-study summary statistics: 
 
( ) ( )∑∑= k kTk k UUQ  K  
 
Here, K  is the kernel matrix that compares multi-site genotypes. A default choice9 is a diagonal matrix
( )Jdiag ωωω ,,, 21 =K , with jω  being the weight assigned to variant site j . The statistic Q  follows 
a mixture chi-square distribution30, with mixture proportions given by the eigenvalues for the matrix 
( ) ( ) 2/12/1 ∑∑ kk kk VKV .  
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Monte-Carlo Method for Empirical Assessment of Significance 
The previous sections describe how a series of gene-level test statistics can be calculated and, for each 
one, propose a strategy for evaluating significance. In practice, evaluating the required numerical integrals 
can be challenging because variance-covariance matrices that are sometimes singular or nearly singular. 
Since single variant test statistics are distributed as: 
( ) ( )∑∑∑ −= kk Tkk k YU ,0MVN~    
To evaluate significance empirically, we sample random vectors from the distribution ( )∑k,0MVN   
and calculate gene level rare variant test statistics for each of these sampled random vectors, allowing us 
to obtain an empirical distribution for any gene-level statistic31. As usual, p-values can then be evaluated 
by comparing the test statistics for the original data with those in this empirical distribution. For 
computational efficiency, we use an adaptive algorithm where a larger number of vectors are sampled 
when assessing small p-values and fewer vectors are sampled when assessing larger p-values19.  
 
Conditional Analyses 
It is well known that, due to linkage disequilibrium, one or more common causal variants can result in 
shadow association signals at other nearby common variants. For common variants, Yang et al25 have 
shown that linkage disequilibrium relationships between variants, estimated from external reference 
panels, can be used to enable conditional analysis in meta-analysis settings. For rare variants and gene-
level tests, accurately describing relationships between variants is crucial and we recommend against the 
use of external reference panels. Instead, in the Supplementary Material, we describe how conditional 
analysis statistics can be derived for different gene-level test in our meta-analysis setting. 
 
Simulation of Population Genetic Data 
We simulated haplotypes using a coalescent model and the program ms15. We chose a demographic model 
consistent with European demographic history4, including an ancestral bottleneck followed by more 
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recent population differentiation and exponential growth. Model parameters were based upon estimates 
from large scale sequencing studies32, as detailed in Supplementary Material.  
 
Meta-Analysis of Lipid Traits 
Summary statistics were calculated for each participating study and shared to enable a central meta-
analysis. In single variant and gene-base rare variant association analysis, age, age2, sex and cohort 
specific covariates, such as principal components of ancestry were included in the analysis. Trait residuals 
were standardized using an inverse normal transformation.  More detailed descriptions for each 
participating cohort are given in the Supplemental Methods.  
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Supplementary Online Methods for 
Meta-Analysis of Gene Level Association Tests 
Dajiang J. Liu et al. 
 
Online Methods: 
We describe a framework for meta-analysis of functional unit level rare variant association tests. The 
approach starts with meta-analysis of single variant association test statistics and then uses these to 
construct test statistics for genes or other functional units. We describe the implementation of several rare 
variant association tests and strategies for conditional analysis, which can provide a useful means of 
disentangling nearby signals. Finally, we propose a Monte Carlo simulation based strategy to aid in 
evaluating significance levels empirically. The document also includes a brief summary of the simulations 
carried out in preparing our manuscript. 
 
Notation  
We consider constructing joint analysis statistics of rare variant association tests using multiple studies. 
For simplicity, we describe our strategy for analysis of a single gene, but the approach naturally extends 
to multiple genes. Let J  be number of variant nucleotide sites of interest genotyped (using arrays or 
sequencing) in at least one of the studies. For study k , let kN  denote the number of samples phenotyped 
and genotyped,
 
and let the vector ( )kNkk kYYY ,,1 ,, =  denote the quantitative trait (or quantitative trait 
residuals) each with variance 2kσ . In all analyses reported here, we applied an inverse normal 
transformation to trait residuals prior to analysis. In our preliminary analyses, this transformation reduced 
the impact of non-normally distributed phenotypes and led to better-behaved quantile-quantile plots.  
Within each study, we encode genotype information in a matrix: 
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Each entry in matrix kjiX ,,  represents the genotype individual i  at site j , coded as the number of 
alternative alleles carried by the individual. We encode missing genotypes in the dataset as the average 
number of alternative alleles in individuals who are genotyped for that marker; alternatively, more 
advanced imputation algorithms (as implemented in MaCH1, IMPUTE22 or BEAGLE3) could be used. 
 
The multi-site genotype for individual i  is denoted by the row vector kiX ,,•

, and the genotypes for all 
kN  individuals at site j  are given by column vector kjX ,,•

. For the ease of presentation, we define the 
mean genotype matrix , where the ),( ji -th element is ( ) ki kji NX∑ ,,  and the centered genotype 
matrix − .  
 
Summary Statistics 
 
For each study, we first calculate a vector of score statistics ( ) kTk YU  −=  and a corresponding 
variance-covariance matrix ( ) ( ) ( )−−== Tkkk N 22 ˆcovˆ σσ . Then, to enable meta-
analysis, we share the following summary statistics between studies: 
a) Score statistics kU

, which can be meta-analyzed across studies and then combined into gene-
level statistics. 
b) The covariance matrix for single variant score statistics . This variance-covariance matrix 
will later allow us to calculate the distribution of gene-level statistics that result from combining several 
single variant score statistics. In principle, sharing the full matrix would allow the most flexibility when 
grouping variants into genes during meta-analysis and for executing conditional analyses. In practice, we 
make two simplifications. First, because the matrix is symmetric, we share only its upper triangle. 
Second, because most gene level tests group nearby variants, we share only covariance information for 
markers <1 Mb apart.  
c) Estimated alternative allele frequencies for each marker ki kjikj NXp 2,,, ∑= , which can be 
used to decide which variants to analyze based on frequency. 
d) Mean and variance for the quantitative trait residuals, for debugging purposes and for quality 
control in multi-sample analyses. As usual, these are ki kik NY∑= ,µˆ  and ( ) ki kkik NY∑ −= 2,2 ˆˆ µσ . 
e) Genotype call rate and p-values for testing Hardy-Weinberg equilibrium at each variant site, 
for quality control and to aid in variant filtering.  
 
Meta-analysis of Single Variant Association Test Statistics 
We first combine single variant association test statistics across studies using the Cochran-Mantel-
Haenszel method. Specifically, we calculate a score statistic at each site as: 
 
•••
=
,,,, jjjj VUT  
 
where ∑=• k kjj UU ,,  and ∑=• k kjjjj VV ,,,, . Cochran-Mantel-Haenszel statistics deal gracefully with 
very rare variants because kjU , . and kjjV ,, remain defined (as zero) even when a variant is monomorphic 
or missing in a study. For ease of presentation, we denote the vector of single variant association tests 
after meta-analysis as ∑= k kUU

. Under the null, this vector is distributed as multivariate normal 
( )∑k,0MVN~ kVU . 
 
Meta-Analysis of Gene-level Rare-Variant Association Tests 
We consider two major types of rare variant association methods: (i) burden tests that assume all variants 
in a gene influence the trait in the same direction, such as the test implemented in the GRANVIL test by 
Morris and Zeggini4 and (ii) methods that allow variants with opposite effects to reside in the same gene, 
such as the variance component score test implemented in  SKAT by Wu et al5. Below, we show that both 
types of method can be derived in a regression model, which allows adjusting for covariates. Furthermore, 
we illustrate how the corresponding gene level statistics can be derived from single site meta-analysis 
statistics and how the information stored in the variance-covariance matrix can be used to enable 
evaluating statistical significance. 
 
Burden Tests That Assume Variants Have Similar Effect Sizes 
For a simple burden test in study k, the impact of multiple rare variants in a region can be modeled using a 
shared regression coefficient BURDENβ  in a regression model that takes the form:  
 
( ) kikiBURDENBURDENkki XCY ,,,,0, εββ ++= • , where ( )2, ,0~ kki σε Ν   
 
( )kiBURDEN XC ,,•  is a function that takes genotypes for a single individual as input and returns the rare 
variant burden for the gene being examined. Popular definitions for ( )kiBURDEN XC ,,•  include simple sum 
statistics and a weighted sum statistic ( ) ∑=• j kjijkiBURDEN XXC ,,,, ω , where jω  is the weight assigned to 
variant j according to its allele frequency or its computationally predicted functional impact6,7. Note that 
in formulating this regression model, we allow the intercept k,0β and residual error 2kσ  to vary between 
studies, but assume that BURDENβ  is shared across studies. For convenience of notation, we define a 
vector of nuisance parameters ( )2
,0 , kkk σβθ =

 and ( )Kθθθ  ,,1= , which are used in the likelihood 
function below. 
 
As usual, the likelihood factors into a product of per study likelihoods: 
 
( ) ( )∏= k kBURDENBURDEN YLYL ,,,,  θβθβ   
 
In joint analysis with individual level data, the score statistic is thus a sum for per study score statistics: 
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Its variance can be derived using the Fisher information matrix,  and following the derivations in Lin and 
Tang7 (who studied a general framework for performing rare variant association tests), it can be shown 
that the variance for the score statistic in joint analysis of all individuals equals the sum of variances in 
each individual study ∑= k kBURDENBURDEN VV , . Therefore, when nuisance parameters are allowed to vary 
between studies, a score test for joint analysis of individual level data (and allowing for study specific 
nuisance parameters) is equivalent to combining per study score statistics via the Cochran-Mantel-
Haenszel method.  
 
The arguments above indicate that the joint analysis statistic for gene-level test can be constructed when a 
per-study kBURDENU ,  statistic is shared. But, because of the simple relationship between burden and single 
variant score statistics in each study (specifically, kTk UU BURDEN

ωβ =, ), the joint analysis statistic for 
gene-level association tests can be calculated using shared single marker statistics. Specifically, the 
burden test score statistics becomes: 
UUUU T
k k
T
k kBURDENBURDEN

ωω === ∑∑ ,  
Under the null, this statistic is approximately normally distributed with mean 0 and variance
( )ωω  ∑= kTBURDENV ! , enabling significance tests. Note that the regression coefficient BURDENβ  can be 
interpreted as a weighted average of single variant effects8. 
 
Variable Threshold Tests with an Adaptive Frequency Threshold 
In variable threshold tests, rare variant burden statistics are calculated for each potential definition of rare 
and significance is evaluated for the maximum of these statistics. Typically, to calculate these statistics all 
unique variant frequencies observed in a gene are listed and each of these frequencies is evaluated as a 
potential frequency threshold. Frequency thresholds can be defined in terms of the pooled minor allele 
frequency or, sometimes, the pooled minor allele count (the two can differ depending on whether samples 
where a variant is missing are assumed to be wild type or unknown).   
 
Given a specific variant frequency threshold F we define a corresponding burden score statistic as: 
 
UvU TFFBURDEN

=)( . 
 
Here, Fv

 is a vector of indicators where the jth element equals 1 if the pooled minor allele frequency at 
variant site j is less than F  and zero otherwise. For convenience of presentation and without loss of 
generality, we also define a matrix of minor allele frequency thresholds ( )
JFFF
vvv
 ,,,
21
=Φ . The 
covariance between burden score statistics 
)(φBURDEN
U  and *)(φBURDENU  calculated for thresholds F and F*, 
is equal to ( ) *)(),( * FkTFFBURDENFBURDEN vv  ∑=Ω ! . After burden statistics are calculated for each potential 
frequency threshold, they are standardized, dividing each statistic by its corresponding variance, and the 
maximum statistic is identified: 
{ },max )(FBURDENFVT TT =  where )(),()()( FBURDENFBURDENFBURDENFBURDEN UT Ω= . 
 
Significance for this statistic can be evaluated using the cumulative distribution function for multivariate 
normal distribution. Specifically, given the definition of the covariance between burden statistics 
calculated using different allele frequency thresholds, we have: 
 
( ) ( )( )ΦΦ ∑kTFBURDENFBURDEN MTT !,0MVN~,, )()( 1  . 
 
Significance tests can be calculated using standard methods for calculating multivariate normal integrals9 
: 
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In practice, the covariance matrix for burden score statistics calculated using different frequency 
thresholds can be singular or nearly so and evaluating the corresponding integrals can be numerically 
challenging. We recommend verifying analytical p-values using simulations (described later in this 
document).    
 
Gene-level Tests that Assume a Distribution of Variant Effect Sizes (e.g. SKAT tests) 
The simple burden test and variable threshold test described above can be underpowered when variants 
with opposite effects on the phenotype reside in the same gene and are grouped together, because the 
shared regression coefficient can average close to zero in that situation. One option in this setting would 
be to model the effects of each rare variant individually – but that strategy consumes many degrees of 
freedom and thus loses efficiency. Instead, we assume an underlying distribution of rare variance effect 
sizes with mean zero and test whether the variance of this distribution, 2τ , is greater than zero. 
 
Specifically, we consider the model:  
 
( )2
,,,,,0, ,0~  where, kkikij kjijkki XY σεεββ Ν++= ∑ , 
 
  
 
and make inferences about rare variant effect sizes ( )Jββββ ,,, 21  =  by assuming these follow a 
common distribution with mean zero and variance 2τ . Under the null, 0=β , which is equivalent to
02 =τ . Following Wu et al5, we consider the likelihood: 
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In order to derive the variance component score statistics for this likelihood, we apply a Laplace 
transformation to the marginal likelihood function, as suggested by Lin10. If repeating this calculation, 
please note that the integrant satisfies:  
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Then, following the argument in Lin10, it can be shown that the variance component score statistics in the 
joint analysis with individual level data for testing 0=τ  is:   
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Therefore, gene level statistics that allow for a distribution of rare variant effect sizes (rather than 
modeling these using a shared regression coefficient) can also be constructed after meta-analysis of single 
variant statistics. Note that Q is a quadratic function of the single site meta-analysis statistics, in contrast 
to burden statistics defined in previous sections, which are linear functions of single site statistics. In 
practice, weights can also be assigned in the variance component score statistics, and the test statistic 
takes the form of ( ) ( )∑∑= k kTk k UUQ  . The matrix K is the kernel that compares multi-site 
genotypes. A default choice is ( )Jdiag ωωω ,,, 21 =K , with jω  being the weight assigned to variant 
site j 5. The statistic Q  follows a mixture chi-square distribution11, with mixture proportions given by 
the eigenvalues for the matrix ( ) ( ) 2/12/1 ∑∑ kk kk VKV .  
 
Monte Carlo Method for Empirical Assessment of Significance 
The previous sections describe how a series of gene-level test statistics can be calculated and, for each 
one, propose a strategy for evaluating significance. In practice, evaluating the required numerical integrals 
can be challenging, because multiple variants or a set of burden scores can produce co-linear sets of 
predictors and variance-covariance matrices that are singular or nearly so. In this section, we describe a 
simple strategy for re-sampling plausible sets of single marker test statistics. Gene level statistics can then 
be evaluated for each of these simulated vectors of single marker test statistics to assess significance 
empirically, in order to avoid some of the problems inherent with numerical integration. 
 
Recall that test statistics are distributed as: 
 
( ) ( )∑∑∑ −= kk Tkk k YU ,0MVN~   
 
To evaluate significance empirically, we sample random vectors from the distribution ( )∑k,0MVN   
and calculate gene level rare variant test statistics for each of these sampled random vectors, allowing us 
to obtain an empirical distribution for any gene-level statistic12. As usual, p-values can then be evaluated 
by comparing the test statistics for the original data with those in this empirical distribution. For 
computational efficiency, we use an adaptive algorithm where a larger number of vectors are sampled 
when assessing small p-values and fewer vectors are sampled when assessing larger p-values13. 
Specifically, we continue sampling new vectors until the number of sampled statistics greater than the 
statistic in the original data exceeds a particular threshold (100, unless noted otherwise) or the total 
number of sampled vectors exceeds a predefined limit (40,000,000; unless noted otherwise).  
 
Conditional Analyses 
It is well known that, due to linkage disequilibrium, one or more common causal variants can result in 
shadow association signals at other nearby common variants. As illustrated in our analysis of the APOE 
locus in the text, common variant association signals can also result in shadow rare variant association 
signals at nearby genes. Conditional analysis provides a useful procedure for disentangling neighboring 
association signals in this setting, for example by checking whether weaker signals remain significant 
after conditioning on nearby strong signals.  
 
For common variants, Yang et al14 have shown that linkage disequilibrium relationships between variants, 
estimated from external reference panels, can be used to enable conditional analysis in meta-analysis 
settings. For rare variants and gene-level tests, accurately describing relationships between variants is 
crucial and we recommend against the use of external reference panels. Instead, we recommend using 
linkage disequilibrium relationships estimated in the samples being analyzed and summarized in the 
variance-covariance matrix of single variant score statistics.  
 
To describe our strategy for conditional analyses, we first decompose the genotype matrix into two 
components: a matrix of genotypes !  for variants to be tested for independent association and a matrix 
of genotypes ! for variants that should be included as covariates in the null regression model (and, thus, 
controlled for). In order to facilitate presentations, we denote ( )!"#$ = . 
 
 
Conditional Analysis for Gene Level Tests That Use A Shared Regression Coefficient for Rare 
Variants 
When individual level data is available, conditional analysis considers a model similar to: 
 
( ) kikiTkkiBURDENkki ZXCY BURDEN ,,,,,0, εαββ +++= •   
 
This analysis could be readily carried out by repeating analysis and calculation of score statistics for each 
study, but this is not required. Instead, the score statistics that result from the conditional analysis 
described above can be readily estimated using summary information.  
 
Let kk BURDENBURDEN UT ,,
~
,
~
ββ  and kBURDENBURDENV ,,
~
ββ  denote test statistics, score statistics and their variances from 
conditional analysis; analogous to statistics previously defined for unconditional analysis. As usual, 
kkk BURDENBURDENBURDENBURDEN VUT ,,,,
~~~
ββββ = . To derive the component statistics, we use the approach of Lin 
and Tang7, to show that: 
( ) ( )( )Tkkkk YYU BURDEN αβ ˆ~ ,  −−−=
 
with =kαˆ ( ) ( )( ) ( ) kY−−− −1 , 
 
and that: 
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with ( ) ( )( ) ( ) ( )( )kkkTkkkk YYYYN ααϕ ˆˆ1ˆ 2  −−−−−−×=  
 
Now, we can verify that kBURDENU ,
~
β  and kBURDENBURDENV ,,
~
ββ  can be calculated using shared summary level 
statistics, because all key terms in the above equations can be extracted from the list of single variant 
score statistics and from the variance-covariance matrix of single marker association test statistics (which 
we have shared), since 
 
( ) ( ) ( ) ( ) ( ) ( )( ) ( ) ( ) ( )





−−−
−
=  . 
 Finally, meta-analysis burden score statistics can be calculated as: 
 
∑∑=• k kk k BURDENBURDENBURDENBURDEN VUT ,,,,
~~~
ββββ . 
 
Thus, conditional statistics after meta-analysis can be calculated from shared single variant statistics and 
their variance-covariance matrix, as desired.  
 
Conditional Analysis for Tests that Assume a Distribution of Rare Variant Effect Sizes (e.g. SKAT) 
Similar arguments can be used to derive formulae for conditional analysis of rare variant association tests 
in settings where direction of effect and effect sizes are allowed to vary between markers. In that setting, 
we follow the approach of Wu et al5. The variance component score test takes the form: 
( ) ( )( ) ( ) ( )( )kkkTkkkk YYYYQ αα ˆˆ~  −−−××−−−= K  
Following the derivation for unconditional analysis, the meta-analysis test statistic is given by : 
( ) ( )( ) ( ) ( )( )( )∑∑ −−−×× −−−= k kkkk Tkkk YYYYQ αα ˆˆ~  K  
Then, noting that the single variant score statistics ( ) ( )( )∑ −−−k Tkkk YY αˆ  follow a 
multivariate normal distribution with mean zero and variance-covariance matrix ∑k kV
~
, where 
( ) ( )( )( )
( ) ( )( )( ) ( )( ) ( ) ( )( )−−−−−
=
−12
2
ˆ
ˆ
~
ϕ
ϕkV
  
It is straightforward to show that Q~  follows a mixture chi-square distribution with mixture proportions 
being the eigenvalues of ( ) ( ) 2/12/1 ~~ ∑∑ . Therefore, score statistics and the variance-covariance 
matrix for single marker statistics, are sufficient to enable derivation of statistics and p-values for 
conditional meta-analysis.  
 
Simulation of Population Genetic Data 
We simulated haplotypes using a coalescent model and the program ms15. We chose a demographic model 
consistent with European demographic history16, including an ancestral bottleneck followed by more 
recent population differentiation and exponential growth (Supplemental Figure 1). Model parameters 
were based upon estimates from large scale sequencing studies17, tuned such that measures of genetic 
diversity between simulated sub-populations match estimates from European samples18. The simulated 
haplotypes had an average pairwise sequence difference of 001.0=pi  and an average 004.0=STF . 
Furthermore, when 5000 haplotypes were sampled, a typical simulated 5000 base pair region included 
~100 variant sites, of which 80% had MAF<1% and ~49% were singletons. For any two pools of 5000 
haplotypes sampled from different subpopulations, ~3% of variants with MAF<1% and 35% of the 
variants with MAF>1% are shared, consistent with expectations from population genetics and 
observations from real data17,19. 
 
Our model assumes an ancestral population with effective population size of 000,101 =N  where an 
instantaneous bottleneck event 3,000 generations in the past reduced population size to Nbottleneck = 75. 
Then, our simulations assume that this population simultaneously split into present day populations 500 
generations before the present. Following the divergence from the ancestral population, the present-day 
populations underwent recent exponential growth, each growing to a present day effective population size 
of 60 101×=N  over 400 generations. We assume equal, symmetric migration rates between the sub-
populations with a per-haplotype, per-generation migration rate of 5×10-4. In the simulation, a per-
basepair, per-generation mutation rate of 2.5×10-8 and a recombination rate equivalent to 1cM/Mb were 
assumed. 
  
Type I Error Rate and Power 
Using simulated genetic data, we estimated power and type I error for each of the methods described here. 
We considered three representative rare variant tests association tests: a simple burden test (with MAF 
thresholds of 1% and 5%), a variable threshold association test, and the SKAT test. First, we generated 
50,000,000 null replicates to evaluate type I error rates in meta-analyses of 3, 6 and 9 samples of 1000 
individuals at significance level α=0.001, 0.0001, or 2.5×10-6. As shown in Supplemental Table 1, the 
type I error rates are well controlled.  
 
Next, the power for different rare variant tests in meta-analysis was evaluated for a series of genetic 
models. In the first set of simulations, 20 or 50% of variants were randomly chosen as causal. In a second 
set of simulations, only variants with MAF<0.5% have potential phenotypic effects and 20 or 50% of 
these variants with MAF<0.5% were selected to be causal at random. In both cases, we considered 
situations where: (i) all causal variants increase expected trait values by 0.25 standard deviations; (ii) 80% 
of causal variants increase trait values by 0.25 standard deviation units, while the remaining 20% decrease 
trait values; (iii) effect sizes for each variant, measured in standard deviation unit, were sampled from a 
normal distribution with mean 0 and variance 0.25.  
 
Supplemental Figures 4 and 5 summarize the results of our power simulations, considering the various 
simulation scenarios and meta-analysis of up to 100 samples of 1000 individuals each. Several patterns 
are clear from the figures. First, for the effect sizes simulated here, very large sample sizes may be 
required to ensure adequate power. In some settings, power only reaches ~60% in analyses that include 
~100,000 individuals, even using the most powerful available test. Second, we did not find a universally 
most powerful method, emphasizing the utility of approaches such as ours that can be extended to 
implement a diverse set of test statistics. Typically, we find that when the proportion of non-causal 
variants is high or causal variants can have opposite effects, the SKAT was more powerful. When causal 
variants have effects in the same direction, simpler burden tests were more powerful.  
 
Supplemental Figure 6 shows that, as expected, pooled analysis of individual level data and meta-
analysis of summary statistics, as proposed here, result in nearly identical power.  
 
Evaluation of Conditional Analysis Strategy 
As described in our analysis of genes neighboring APOE, common variant association signals can 
produce inflated rare variant test statistics at nearby genes due to linkage disequilibrium. To evaluate our 
strategy for conditional analysis of rare variant association tests, we selected one common variant with 
pooled MAF>10% as causal and increase the mean trait value by 0.25 standard deviation. We then 
evaluated the type I error rate of gene-level rare variant association test statistics (Supplemental Figure 
8). The results show that, without conditioning, p-values deviate substantially from null expectations. The 
results also show that, after conditioning, p-values for rare variant association tests behave as expected 
under the null.  
 
Meta-Analysis of Lipid Traits 
Summary statistics were calculated for each participating study and shared to enable a central meta-
analysis. In single variant and gene-base rare variant association analysis, age, age2, sex and cohort 
specific covariates, such as principal components of ancestry were included in the analysis. Trait residuals 
were standardized using an inverse normal transformation.   
 
STUDY DESCRIPTIONS 
Malmö Diet and Cancer Study – Cardiovascular Cohort (MDC-CC)  
The Malmö Diet and Cancer Study20 is a community-based prospective epidemiologic cohort of 28,449 
persons recruited for a baseline examination between 1991 and 1996. From this cohort, 6,103 persons 
were randomly selected to participate in the cardiovascular cohort, which sought to investigate risk 
factors for cardiovascular disease. All participants underwent a medical history assessment and a physical 
examination.  
 
Women’s Health Initiative 
The WHI21 encompasses four randomized clinical trials as well as a prospective cohort study of 161,808 
post-menopausal women aged 50–79, recruited (1993–1998) and followed up at 40 centers across the US. 
Samples examined here were genotyped as part of the NHLBI Exome Sequencing Project. 
 
Ottawa Heart Study 
Cases and controls were recruited from either the lipid clinic at the University of Ottawa Heart Institute or 
the cardiac catheterization laboratory22.  All cases were required to have at least one of: a stenosis in a 
major epicardial vessel of at least 50%; have had a percutaneous intervention (PCI); have had coronary 
artery bypass surgery (CABG); or have had a myocardial infarction (MI). Cases with diabetes mellitus 
were excluded. Age of onset of CAD was required to be ≤55 years old for men and ≤65 years old for 
women. Controls were either healthy asymptomatic elderly individuals or were recruited through the 
catheterization laboratory with no stenosis ≥50% in any major epicardial vessel and were required to be 
≥65 years old for men and ≥70 years old for women.  
 
PROCARDIS 
The PROCARDIS23 “genetically-enriched” case collection is composed of sibships (proband and at least 
one affected sibling) with coronary disease.  Ascertainment criteria for PROCARDIS probands were 
myocardial infarction (MI) or symptomatic acute coronary syndrome before the age of 66 years.  For each 
of the coronary disease cases included in the “genetically-enriched” case-control study, it was planned to 
recruit one control of the same sex, ethnicity and within 5 years of age of cases, with no personal or 
sibling history of coronary disease before age 66 years.  In the UK, controls were identified by mailing a 
self-administered questionnaire to spouses or siblings of spouses or male friends of any individuals who 
had previously returned a completed questionnaire to the PROCARDIS study.  Eligible respondents were 
asked to attend their general practice to have their blood pressure, height and weight recorded, and to 
provide a blood sample.  In Sweden, Italy and Germany, controls were selected from population registers 
and invited to attend a special clinic to have their blood pressure, height and weight recorded, to provide a 
blood sample and to complete a self-administered questionnaire.  
 
HUNT – The Nord-Trøndelag Health Study 
The HUNT study has been described in detail previously24. The HUNT study is a population based health 
study with personal and family medical histories on 106,436 people from Nord-Trøndelag County, 
Norway, collected during three phases from 1984 to 2008. A subsample of 5,869 individuals were 
successfully genotyped on the iSelect Exomchip V1.0 (Illumina, San Diego, CA), 2,928 cases with 
retrospectively hospital diagnosed myocardial infarction and 2,941 healthy controls matched on sex, birth 
year and municipality. Genotype calling was done using GenTrain version 2.0 in GenomeStudio V2011.1 
(Illumina, San Diego, CA) in combination with zCall version 2.2 25.  
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Supplemental Figure 1: Demographic model for simulated European populations. The demographic 
model includes an ancient population bottleneck, recent exponential growth, differentiation and 
migration. The model parameters were calibrated to mimic populations sampled in continental Europe.  
 
 
 
  
Supplemental Figure 2: Comparison of statistics and p-values for a simple burden test, variable 
threshold (VT) and sequence kernel association test (SKAT) in analysis of pooled samples (X-axis) and in 
meta-analysis (Y-axis). Three samples of 1000 individuals were simulated. Traits were generated 
assuming that 50% of the variants are causal and that, among these, 80% of the variants increase the trait 
values by 0.25 standard deviation units and the remaining 20% decrease trait values by the same amount. 
Empirical p-values for the variable threshold (VT) test were obtained using the adaptive Monte Carlo 
procedure, stopping after 100 simulated statistics were greater than the original statistic or the number of 
simulations exceeded 40,000,000.  
 
 
Supplemental Figure 3: Comparison of statistics and p-values for a simple burden test, variable 
threshold (VT) and sequence kernel association test (SKAT) in analysis of pooled samples (X-axis) and in 
meta-analysis (Y-axis). This Figure is analogous to Supplementary Figure 2, but assumes a random 
effect for each causal variant, distributed as Normal(0.25, 0.01) in standard deviation units.  
 
  
Supplemental Figure 4: Power of meta-analysis rare variant association tests as a function of the number 
of studies in the meta-analysis, each with 1000 individuals. Quantitative trait data were simulated 
assuming the trait was influenced by rare variants with frequency less than 5%.  In panel A, 20% of the 
variants with MAF <5% are causal and each increases trait values by 0.25 standard deviation units. In 
panel B, 50% of the variants with MAF <5% are causal and each increases trait values by 0.25 standard 
deviation units. In panel C, 20% of the variants with MAF <5% are causal, with 80% of these increasing 
the trait by 0.25 standard deviation units with the other 20% decreasing trait values by the same amount. 
In panel D, 50% of the variants with MAF <5% are causal, with 80% of these increasing the trait by 0.25 
standard deviation units while the other 20% decreasing trait values by the same amount. 
 
  
 
Supplemental Figure 5: Power of meta-analysis rare variant association tests as a function of the number 
of studies in the meta-analysis, each with 1000 individuals. Quantitative trait data were simulated 
assuming the trait was influenced by rare variants with frequency less than 0.5%.  In panel A, 20% of the 
variants with MAF <0.5% are causal and each increases trait values by 0.25 standard deviation units. In 
panel B, 50% of the variants with MAF <0.5% are causal and each increases trait values by 0.25 standard 
deviation units. In panel C, 20% of the variants with MAF < 0.5% are causal, with 80% of these 
increasing the trait by 0.25 standard deviation units with the other 20% decreasing trait values by the 
same amount. In panel D, 50% of the variants with MAF < 0.5% are causal, with 80% of these increasing 
the trait by 0.25 standard deviation units while the other 20% decreasing trait values by the same amount. 
 
 
  
  
Supplemental Figure 6: Power comparison of meta-analysis and analysis of pooled individual level data 
(“Mega-Analysis”). Data were simulated for 20 samples of 1000 individuals each. Results are shown 
when (a) 20% of simulated variants are causal and each increase expected trait values by 0.25 standard 
deviation units; (b) 50% of the variants are causal and increase trait values by 0.25 standard deviation 
units; (c) 20% of variants are causal, with 80% increasing trait values by 0.25 standard deviation units and 
the remaining 20% decreasing trait values by the same amount; (d) 50% of variants are causal, with 80% 
increasing trait values by 0.25 standard deviation units and the other 20% decreasing trait values by the 
same amount.  
 
  
Supplemental Figure 7: Power comparison for our approach, Fisher’s method and the minimal p-value 
approach. Three phenotype models were simulated: (A) half of low frequency variants with MAF < 0.5% 
are causal, each increasing expected trait values by 1/4 standard deviation; (B) half of all variants are 
causal, irrespective of frequency, and increase trait values by 1/4 standard deviation; (C) 50% of the 
variants are casual, irrespective of frequency, and 80% of these increase expected trait values by 1/4 
standard deviation, while the remaining 20% decrease trait values by the same amount. Three samples of 
size 10,000 were simulated for each model, and meta-analysis was performed using either our approach 
or using Fisher’s method and the minimal p-value approach to combine burden test, SKAT and variable 
threshold (VT) test statistics for variants with MAF<5%. The power was evaluated at the significance 
threshold of α=2.5×10-6 using 10,000 replicates. Note that differences between our approach and these 
alternatives become more marked when sample sizes for individual studies differ and/or when more 
studies are meta-analyzed. 
 
Supplemental Figure 8: Comparison of meta-analysis and analysis of pooled individual level data in the 
Malmö Diet and Cancer Study – Cardiovascular Cohort (MDC). Our largest sample, the MDC study was 
split into 4 sub-samples of comparable size. LDL-cholesterol values in each sub-sample were 
standardized using an inverse-normal transformation. Summary level statistics were generated for each 
sub-sample and meta-analyses was performed combining summary statistics from 4 studies. Results of 
the original analysis of the MDC study are also shown.   
 
Supplemental Figure 9: Quantile-Quantile plot of p-values for single variant meta-analysis. Log-
transformed observed and expected p-values are displayed for high density lipoprotein cholesterol (panels 
A-B), low density lipoprotein cholesterol (C-D) and triglyceride levels (E-F), either using all variants (left 
column) and variants with MAF < 5% (right column).  
 
  
Supplemental Figure 10 (Part 1 of 3): Quantile-quantile plot of p-values for gene-level meta-analysis. 
Log-transformed observed and expected p-values are displayed for high density lipoprotein cholesterol 
(panels A-E), low density lipoprotein cholesterol (F-J) and triglyceride levels (K-O). 
 
  
Supplemental Figure 10 (Part 2 of 3):
 
  
Supplemental Figure 10 (Part 3 of 3):
 
  
Supplemental Figure 11: Quantile-quantile plot for log-transformed p-values comparing the distribution 
of p-values in a conditional analysis (on the left) and an unconditional analysis (on the right). One 
hundred samples were simulated. In each simulation, a single common variant (with MAF>10%) was 
marked as causal, increasing expected trait values by 0.25 standard deviation units. A series of rare 
variant association analysis were then carried out, with (left) or without (right) conditioning on the effect 
of this common variant. The result clearly shows that, without conditioning, rare variant association test 
statistics are inflated. 
   
Supplemental Figure 12: Comparison of conditional meta-analysis and conditional analysis of pooled 
individual level data in the Malmö Diet and Cancer Study – Cardiovascular Cohort (MDC). Our largest 
sample, the MDC study was split into 4 sub-samples of comparable size. LDL-cholesterol values in each 
sub-sample were standardized using an inverse-normal transformation. Summary statistics were generated 
for each sub-sample. Conditional association analysis was performed in the pooled sample by controlling 
for the most significant single nucleotide polymorphism (rs7412) in gene APOE. Conditional evidence for 
association at sixty-six genes within 1Mb of rs7412 was evaluated, either using our meta-analysis 
approach (X axis) or by analyzing individual level data directly (Y axis). The genes examined were 
TOMM40, APOE, OPA3, ERCC1, MARK4, FOSB, PVRL2, CKM, CLPTM1, RTN2, ZNF155, ZNF230, 
ZFP112, ZNF225, ZNF223, ZNF221, ZNF222, DMPK, ZNF45, CEACAM19, CLASRP, BCL3, EML2, 
SIX5, GEMIN7, PPP1R13L, FBXO46, PVR, CBLC, LOC100379224, ZNF227, ZNF235, ZNF285, 
CEACAM20, ZNF296, NKPD1, TRAPPC6A, BLOC1S3, KLC3, PPM1N, IRF2BP1, MYPOP, ERCC2, 
ZNF226, CD3EAP, GIPR, ZNF180, DMWD, BCAM, SYMPK, ZNF229, RSPH6A, ZNF234, VASP, 
APOC4, APOC1, FOXA3, EXOC3L2, RELB, ZNF224, APOC4-APOC2, APOC2, CEACAM16, ZNF284, 
QPCTL, ZNF233.  
  
  
Supplemental Figure 13: Comparison of conditional meta-analysis and conditional analysis of pooled 
individual level data in the Malmö Diet and Cancer Study – Cardiovascular Cohort (MDC). Our largest 
sample, the MDC study was split into 4 sub-samples of comparable size. LDL-cholesterol values in each 
sub-sample were standardized using an inverse-normal transformation. Summary level statistics were 
generated for each sub-sample. C onditional association analysis was performed in the pooled sample 
conditional on three common single nucleotide polymorphism (rs6511720, rs2228671 and rs72658855) in 
gene LDLR that each reach significant evidence for association. A total of 59 genes within 1Mb of these 
top 3 SNPs were analyzed, either using our meta-analysis approach (X axis) or by analyzing individual 
level data directly (Y axis). Test statistics were evaluated at DNM2, S1PR5, LOC55908, ZNF844, 
CCDC151, TYK2, ZNF440, ZNF491, CNN1, SLC44A2, SMARCA4, KEAP1, ICAM3, KANK2, ICAM1, 
RAVER1, EPOR, ICAM4, ZNF439, ILF3, DNMT1, PRKCSH, TMED1, KRI1, QTRT1, C19orf38, 
C19orf52, SPC24, TMEM205, C19orf39, ECSIT, ZNF441, ZNF69, ZNF700, ZNF433, AP1M2, TSPAN16, 
ACP5, RGL3, LDLR, YIPF2, CDKN2D, S1PR2, ZGLP1, ZNF653, LPPR2, DOCK6, PDE4A, ZNF627, 
CCDC159, ATG4D, RAB3D, CARM1, ICAM5, MRPL4, ZNF823, FDX1L, ZNF763, ZNF878.  
 
 
  
Supplemental Table 1: Evaluation of type I error rates for meta-analysis methods. Type I error rates 
were evaluated for three rare variant tests (burden-1: a simple burden test group variants with <1% 
frequency, VT: a variable threshold association test, SKAT-1: a sequence kernel association test focused 
on variants with frequency <1% and allowing for variants with opposite effects to reside in the same 
gene). Significance levels α=0.001, 0.0001, and 2.5×10-6 were considered. Data were generated for meta-
analysis of 3, 6 and 9 samples of 1000 individuals. The type I error estimates are based upon 5×107 null 
simulations. 
  
Number of Studies Burden-1 VT SKAT-1 
α=1×10-3 
3 9.9×10-4 1.0×10-3 9.4×10-4 
6 1.0×10-3 1.0×10-3 9.8×10-4 
9 1.0×10-3 1.0×10-3 1.0×10-3 
α=1×10-4 
3 9.9×10-5 1.1×10-4 9.2×10-5 
6 1.1×10-4 1.2×10-4 9.9×10-5 
9 1.0×10-4 1.1×10-4 9.9×10-5 
α=2.5×10-6 
3 2.2×10-6 2.6×10-6 2.5×10-6 
6 2.4×10-6 2.6×10-6 2.6×10-6 
9 2.2×10-6 1.6×10-6 2.2×10-6 
 
  
 Supplemental Table 2: Summary trait and variant information. In each study, medians and interquartile ranges are tabulated for age, sex and lipid 
traits, together with the number of genotyped non-synonymous and loss-of-function variants. Participating studies were the Malmo Diet and 
Cancer (MDC) study, the Ottawa Heart study, the Women’s Health Initiative Sequencing Project (WHISP), Procardis and HUNT. Genotyped 
samples in Procardis and HUNT are separated into heart disease cases and controls.   
 
Study 
Age HDL LDL TG 
Total 
Number of 
Individuals 
Proportion 
of Males 
Number of Variants 
Median (Interquartile Range) Lipids Level (mg/dL) All 
Nonsynonymous 
+ 
Loss of Function 
Nonsynonymous 
+ 
Loss of 
Function, MAF 
<1% 
Malmo Diet and Cancer 58 (10.4) 51.4 (18.9) 158.3 (50.2) 102.7 (65.5) 4924 40.8% 130,621 111,127 90,317 
Ottawa Heart Study 72 (13.1) 50.6 (20.9) 139.4 (48.3) 121.2 (100.0) 2938 60.0% 116,173 97,628 77,866 
WHISP European 
Americans 68 (7.0) 56.0 (22.0) 140.2 (48.1) 139.0 (87.0) 2031 0.0% 110,678 91,998 70,421 
PROCARDIS (Cases) 58 (10.0) 46.0 (17.0) 142.0 (54.3) 159.0 (120.0) 2070 48.9% 97,887 79,551 58,864 
PROCARDIS (Controls) 66 (7.0) 53.9 (20.5) 129.9 (42.2) 123.1 (88.5) 1299 62.1% 105,255 86,639 66,114 
HUNT (Cases) 66(18.0) 46.3(15.4) 162.2(57.9) 177 (123.9) 2659 65.5% 90,340 72,866 52,133 
HUNT (Controls) 65(19.0) 50.2(19.3) 154.4(54.1) 141.6 (86.7) 2778 66.1% 91,902 74,366 53,682 
Supplemental Table 3 Variants sites shared between studies, by frequency. The number of shared variant nucleotide sites are displayed 
respectively for each pair of studies and for variant sites with MAF > 1% and with MAF≤ 1%. Tabulated studies include the Malmo Diet and 
Cancer (MDC) study, the Ottawa Heart Study (Ottawa), European American Samples from the WHISP study, and case and control samples from 
Procardis and HUNT. 
 
 
MDC Ottawa 
WHISP 
European 
Americans 
PROCARDIS 
(Cases) 
PROCARDIS 
(Controls) 
HUNT 
(Cases) 
HUNT 
(Controls) 
 Variants with MAF > 1% 
MDC  36,520   33,546   34,414   34,925   34,903   34,263   34,251  
Ottawa     34,981   34,472   34,311   34,265   33,178   33,183  
WHISP European Americans        37,256   35,090   35,020   33,942   33,929  
PROCARDIS (Cases)           36,484   35,609   34,370   34,390  
PROCARDIS (Controls)              36,283   34,317   34,327  
HUNT (Cases)                 36,140   35,516  
HUNT (Controls)        36,098  
 Variants with MAF ≤ 1% 
MDC  94,101   57,932   53,613   48,682   53,051   44,583   45,773  
Ottawa     81,192   55,396   47,528   52,283   39,414   40,493  
WHISP European Americans        73,422   43,892   47,858   36,627   37,614  
PROCARDIS (Cases)           61,403   45,837   35,867   36,670  
PROCARDIS (Controls)              68,972   38,204   39,061  
HUNT (Cases)                 54,200   45,054  
HUNT (Controls)        55,804  
 
 Supplemental Table 4: Results for single variant meta-analysis. Loci that are statistically significant after Bonferroni correction (with p < 3×10-7) 
are shown. In each locus, p-value, annotation, reference and alternative allele, alternative allele frequency as well as genetic effect estimate and 
standard deviation are displayed for the variant with the most significant p-value.  
 
Gene 
Gene 
Positiona P-value rs# Annotation Ref/Alt 
Frequency 
for 
Alt Allele 
Estimated Effect 
Size for Alt Allele 
(in standard 
deviation units) 
Standard Error 
for  
Estimated Effect 
(in standard  
deviation units) 
HDL 
LPL chr8:19.8Mb 1.17×10-18 rs268 Nonsynonymous A/G 0.02454 -0.2963 0.001129 
ANGPTL4 chr19:8.4Mb 3.61×10-18 rs116843064 Nonsynonymous G/A 0.02649 0.2809 0.001045 
LIPG chr18:47.1Mb 7.26×10-15 rs77960347 Nonsynonymous A/G 0.01346 0.3484 0.002006 
CD300LG chr17:41.9Mb 3.00×10-10 rs72836561 Nonsynonymous C/T 0.03327 -0.1815 0.00083 
LIPC chr15:58.9Mb 5.10×10-10 rs113298164 Nonsynonymous C/T 0.003675 0.5356 0.007425 
APOB chr2:21.2Mb 2.24×10-9 rs533617 Nonsynonymous T/C 0.0397 0.1592 0.000709 
HNF4A chr20:43.0Mb 2.64×10-7 rs1800961 Nonsynonymous C/T 0.041 -0.1342 0.00068 
LDL 
PCSK9 chr1:55.5Mb 2.60×10-28 rs11591147 Nonsynonymous G/T 0.01311 -0.5112 0.002146 
BCAM chr19:45.3Mb 2.64×10-24 rs28399653 Nonsynonymous G/A 0.03509 -0.2896 0.00081 
CBLC chr19:45.3Mb 2.99×10-22 rs3208856 Nonsynonymous C/T 0.03678 -0.27 0.000774 
PVR chr19:45.2Mb 1.71×10-9 rs1058402 Nonsynonymous G/A 0.0487 -0.1458 0.000586 
APOB chr2:21.2Mb 6.70×10-9 rs5742904 Nonsynonymous C/T 0.000633 1.211 0.043597 
TG 
ANGPTL4 chr19:8.4Mb 8.55×10-24 rs116843064 Nonsynonymous G/A 0.0265 -0.3248 0.001043 
LPL chr8:19.8Mb 1.70×10-19 rs268 Nonsynonymous A/G 0.02472 0.3022 0.00112 
APOB chr2:21.2Mb 1.81×10-10 rs533617 Nonsynonymous T/C 0.03967 -0.1697 0.000708 
MAP1A chr15:43.8Mb 1.10×10-7 rs55707100 Nonsynonymous C/T 0.026 0.1732 0.001065 
a. Gene position is defined based upon hg19, GRCh37 Genome Reference Consortium Human Reference 37 
  
Supplemental Table 5 (Part 1 of 3): Comparison of meta-analysis and analysis of individual studies for gene-level tests. Results for six rare 
variant tests are shown (burden-5: a simple burden test group variants with <5% or <1% frequency, VT: a variable threshold association test, 
SKAT-5: a sequence kernel association test focused on variants with <5% or <1% frequency and allowing for variants with opposite effects to 
reside in the same gene). For tests that assume that model the average effect of variants in a gene, a + or – sign indicates whether these variants 
raised (+) or lowered (-) trait levels on average. Overall, the results show that, for these genes, meta-analysis results in a substantially stronger 
signal than analysis of any single sample and that the direction of effect for these top signals is generally consistent across studies. Study 
abbreviations are as in previous tables. 
 
Gene Meta Analysis MDC Ottawa WHISP 
PROCARD
IS (Cases)  
PROCARD
IS 
(Controls) 
HUNT  
(Cases) 
HUNT 
(Controls) 
Burden-5 
HDL 
LPL 2×10-24/- 5×10-11/- 4×10-5/- 0.007/- 5×10-4/- 0.004/- 0.002/- 0.001/- 
ANGPTL
4 3×10-19/+ 2×10-5/+ 2×10-6/+ 0.04/+ 0.1/+ 0.006/+ 0.03/+ 4×10-6/+ 
LIPG 6×10-19/+ 1×10-8/+ 0.03/+ 0.2/+ 0.003/+ 0.04/+ 5×10-7/+ 0.001/+ 
HNF4A 3×10-7/- 0.009/- 5×10-4/- 0.003/- 0.7/+ 0.002/- 0.8/- 0.08/- 
LIPC 4×10-7/+ 8×10-4/+ 0.4/+ 0.4/+ 0.5/+ 0.3/+ 0.007/+ 9×10-4/+ 
CD300LG 8×10-7/- 0.04/- 0.002/- 0.1/- 0.8/+ 0.09/- 0.7/- 1×10-4/- 
LDL 
PCSK9 7×10-19/- 5×10-5/- 1×10-9/- 5×10-7/- 0.02/- 0.001/- 0.02/- 0.06/- 
BCAM 2×10-18/- 6×10-6/- 0.4/- 0.02/- 0.01/- 0.01/- 0.03/- 3×10-6/- 
CBLC 2×10-15/- 3×10-7/- 0.1/- 0.3/- 0.2/- 5×10-5/- 0.002/- 2×10-4/- 
PVR 3×10-10/- 2×10-5/- 0.02/- 0.05/- 0.01/- 0.2/- 0.1/+ 0.3/- 
TG 
ANGPTL
4 1×10-24/- 3×10-6/- 9×10-6/- 2×10-6/- 0.01/- 0.005/- 0.002/- 2×10-6/- 
LPL 8×10-20/+ 1×10-9/+ 0.001/+ 5×10-4/+ 0.001/+ 0.2/+ 0.04/+ 5×10-5/+ 
 
Supplemental Table 5 (Part 2 of 3). 
Gene Meta Analysis MDC Ottawa WHISP 
PROCARD
IS (Cases)  
PROCARD
IS 
(Controls) 
HUNT  
(Cases) 
HUNT 
(Controls) 
SKAT-5 
HDL 
ANGPTL
4 3×10-19/+ 5×10-5/+ 2×10-6/+ 0.03/+ 0.02/+ 0.03/+ 0.04/+ 7×10-6/+ 
LPL 5×10-13/- 8×10-6/- 0.003/- 0.08/- 0.07/- 0.1/- 0.1/- 0.05/- 
LIPG 3×10-9/+ 3×10-4/+ 0.04/+ 0.4/+ 0.03/+ 0.2/+ 0.002/+ 0.07/+ 
HNF4A 3×10-7/- 0.009/- 4×10-4/- 0.003/- 0.8/+ 0.003/- 0.8/- 0.08/- 
LDL 
PCSK9 6×10-17/- 8×10-4/- 4×10-7/- 3×10-9/- 0.003/- 3×10-5/- 0.2/- 0.1/- 
TG 
ANGPTL
4 4×10-25/- 4×10-6/- 8×10-6/- 8×10-6/- 0.006/- 0.02/- 0.005/- 1×10-5/- 
LPL 2×10-11/+ 5×10-7/+ 0.02/+ 0.02/+ 0.1/+ 0.3/+ 0.2/+ 0.02/+ 
 
  
Supplemental Table 5 (Part 3 of 3). 
VT 
HDL 
LPL 1×10-23/- 1×10-10/- 2×10-4/- 0.02/- 0.002/- 0.02/- 0.006/- 0.003/- 
ANGPTL
4 2×10-18/+ 1×10-4/+ 2×10-5/+ 0.1/+ 0.4/- 0.02/+ 0.07/+ 2×10-5/+ 
LIPG 4×10-18/+ 6×10-8/+ 0.04/- 0.4/- 0.01/+ 0.1/+ 1×10-6/+ 0.003/+ 
LIPC 4×10-12/+ 0.003/- 0.2/- 0.5/- 0.8/- 0.7/- 1×10-4/- 4×10-7/- 
LDL 
PCSK9 2×10-28/- 2×10-5/- 3×10-9/- 2×10-6/- 0.001/- 9×10-6/- 0.08/- 0.008/- 
BCAM 3×10-17/- 9×10-5/- 0.7/- 0.007/- 0.01/- 0.003/- 0.07/- 4×10-6/- 
CBLC 1×10-14/- 7×10-7/- 0.4/- 0.06/+ 0.06/- 3×10-4/- 0.01/- 0.001/- 
PVR 1×10-9/- 8×10-5/- 0.08/- 0.2/- 0.06/- 0.3/- 0.3/+ 0.7/+ 
LDLR 2×10-7/+ 0.1/- 0.001/- 0.2/- 5×10-4/- 0.1/- 0.03/- 0.008/- 
TG 
ANGPTL
4 7×10-24/- 1×10-5/- 5×10-5/- 6×10-6/- 0.04/+ 0.01/- 0.005/- 7×10-6/- 
LPL 5×10-19/+ 4×10-9/+ 0.006/+ 0.001/+ 0.005/+ 0.6/+ 0.06/- 2×10-4/+ 
 
Burden-1 
HDL 
LIPC 1×10-12/+ 0.004/+ 0.05/+ 0.2/+ 0.7/+ 0.8/+ 4×10-5/+ 1×10-7/+ 
 
SKAT-1 
HDL 
LIPC 2×10-9/+ 0.07/+ 0.1/+ 0.08/+ 0.7/+ 0.8/+ 0.001/+ 3×10-5/+ 
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Supplemental Table 6: Comparison of gene-level test results with single variant association tests. For each locus identified using gene-level 
association tests, we show the rs number, ref/alt allele, alt allele frequency and p-value for the variant site that displays the most significant p-
value. The loci where one or more gene-based association signal exceeds the top single variant association signal are labeled with an asterisk.  
Gene Burden-1 Burden-5 SKAT-1 SKAT-5 VT 
MAF 
Cutoff 
Top Single Variant Association(MAF<5%) 
rs Number Ref/Alt p-value AF 
HDL 
LIPC* 1.4×10-12 3.5×10-7 1.8×10-9 1.4×10-2 4.5×10-12 3.7×10-3 rs113298164 C/T 5.1×10-10 3.68×10-3 
LPL* 0.97 2.5×10-24 0.35 5.0×10-13 1.5×10-23 0.025 rs268 A/G 1.2×10-18 0.025 
ANGPTL4* 0.022 2.9×10-19 0.022 3.0×10-19 1.8×10-18 0.026 rs116843064 G/A 3.6×10-18 0.027 
LIPG* 2.2×10-5 6.4×10-19 2.1×10-5 2.9×10-9 4.4×10-18 0.013 rs77960347 A/G 7.3×10-15 0.014 
HNF4A 0.74 2.8×10-7 0.68 2.5×10-7 1.5×10-6 0.041 rs1800961 C/T 2.6×10-7 0.041 
CD300LG 0.49 8.5×10-7 0.52 1.0×10-5 3.1×10-6 0.033 rs72836561 C/T 3.0×10-10 0.033 
LDL 
PCSK9* 1.8×10-2 7.4×10-19 0.081 5.5×10-17 2.0×10-28 0.013 rs11591147 G/T 2.6×10-28 0.013 
BCAM 0.17 1.6×10-18 0.15 3.0×10-5 2.6×10-17 0.036 rs28399653 G/A 2.6×10-24 0.035 
CBLC 0.94 2.0×10-15 0.44 1.5×10-4 1.0×10-14 0.044 rs3208856 C/T 3.0×10-22 0.037 
PVR 0.061 3.0×10-10 0.048 0.063 1.1×10-9 0.049 rs1058402 G/A 1.7×10-9 0.049 
LDLR* 1.8×10-3 4.7×10-5 0.038 0.25 2.4×10-7 5.2×10-4 rs139791325 G/A 7.68×10-4 5.2×10-4 
TG 
ANGPTL4* 0.026 1.2×10-24 0.037 3.9×10-25 7.1×10-24 0.026 rs116843064 G/A 8.6×10-24 0.027 
LPL* 0.68 7.7×10-20 0.26 1.8×10-11 4.6×10-19 0.025 rs268 A/G 1.7×10-19 0.025 
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Supplemental Table 7: Results of conditional association analysis for trait LDL and variants in gene LDLR. We performed conditional 
association analysis for variants in LDLR, conditioning on 3 common variants (rs6511720, rs2228671 and rs72658855) that are statistically 
significant in single variant association analysis (i.e. with p-value <3×10-7). The rs number, reference, alternative alleles, minor allele frequencies, 
p-values before and after conditioning on top variants, the estimates of genetic effects for alternative alleles, and annotation information are 
displayed for non-synonymous and loss-of-function variants.  
Single Variant Association Analysis 
RS Ref Alt MAF 
Un-
conditional P-
value  
Conditional 
P-value 
Un-
conditional 
Betaa 
Conditiona
l Betaa Anno 
rs6511720 G T 0.1083 2×10-38 - -0.22 - Intron 
rs2228671 C T 0.1145 4×10-22 - -0.16 - Synonymous 
rs2738459 A C 0.4908 4×10-8 - -0.06 - Intron 
rs11669576 G A 0.046 8×10-4 0.201 0.08 0.03 Nonsynonymous 
rs139624145 G A 0.0001 8×10-4 0.001 1.68 1.61 Nonsynonymous 
rs139791325 G A 0.0005 8×10-4 0.002 0.77 0.7 Nonsynonymous 
rs199774121 C A 3×10-5 0.004 0.002 2.88 3.14 Stop_Gain 
rs144172724 G A 3×10-5 0.024 0.037 2.26 2.11 Nonsynonymous 
rs141673997 G A 3×10-5 0.048 0.056 1.98 1.92 Nonsynonymous 
rs150673992 C T 6×10-5 0.056 0.031 1.35 1.54 Nonsynonymous 
rs28942084 C T 6×10-5 0.151 0.158 1.02 1.01 Nonsynonymous 
rs139043155 T A 0.0001 0.21 0.241 0.63 0.59 Nonsynonymous 
rs139361635 G A 3×10-5 0.266 0.2 1.11 1.29 Nonsynonymous 
rs143992984 G A 8×10-5 0.358 0.233 0.53 0.7 Nonsynonymous 
rs137853963 G A 0.0018 0.391 0.212 -0.11 -0.16 Nonsynonymous 
rs13306505 C T 6×10-5 0.511 0.47 0.47 0.51 Nonsynonymous 
rs148698650 G A 0.0001 0.539 0.585 0.27 0.25 Nonsynonymous 
rs200727689 G A 3×10-5 0.603 0.667 0.52 0.43 Nonsynonymous 
rs5928 G A 3×10-5 0.892 0.851 -0.14 -0.19 Nonsynonymous 
rs146200173 C G 0.0002 0.997 0.99 0 0 Nonsynonymous 
Gene-level Test 
Gene P-value before Conditioning 
P-value after 
Conditioning 
MAF cutoff 
before 
conditioning 
MAF cutoff after 
conditioning 
Estimate of Genetic 
Effect Before 
Conditioninga  
Estimate of Genetic Effect 
After Conditioninga 
LDLR 2.4×10-7 4.6×10-7 5.2×10-4 5.2×10-4 0.75 0.73 
a. Estimates are calculated in standard deviation units. 
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Supplemental Table 8: Results of conditional association analysis for trait LDL and locus APOE-BCAM-CBLC-PVR. We performed conditional 
association analysis conditioning on the top variant (rs7412) that are statistically significant in single variant association analysis (i.e. with p-value 
<3×10-7). The p-values before and after conditional analysis for burden test and SKAT tests with 5% MAF cutoff and VT test that analyzes variant 
with MAF<5% are shown. The rs number, reference, alternative alleles, p-values before and after conditioning on rs7412 were also displayed for 
each gene.  
Gene 
Burden-5 
 
SKAT-5 
 
VT 
 
Top SNP 
Un-
conditional Conditional 
Un-
conditional 
Conditiona
l 
Un-
conditional 
Conditiona
l RS Ref Alt Un-conditional Conditional 
BCAM 1.57×10-18 0.89 3.01×10-5 0.42 2.61×10-17 0.80 rs28399653 G A 2.64×10-24 0.67 
CBLC 1.98×10-15 0.02 1.47×10-4 0.41 9.99×10-15 0.09 rs3208856 C T 2.99×10-22 0.76 
PVR 2.97×10-10 0.14 6.30×10-2 0.62 1.13×10-9 0.39 rs1058402 G A 1.71×10-9 0.27 
 
 
